Novasenta
PrivateLast Round
Series B
Feb 5, 2024
Est. Valuation
$78M
Total Funding Raised
$75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Novasenta operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Series B round in February 2024.
Novasenta is a biotechnology company that develops innovative immuno-oncology therapeutics and utilizes a machine-learning platform to discover potential drug targets within the tumor microenvironment, aiming to provide safer and more effective cancer treatments.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Novasenta Comparables
Compare Novasenta with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Coherus BioSciences Inc | 81% | |
| Asher Biotherapeutics | 79% | |
| NextCure Inc | 76% |
For institutional investors. Book with your work email.
Novasenta Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 5, 2024 | ||||
| Series A | Jul 29, 2022 | ||||
| Seed | Aug 23, 2021 |
For institutional investors. Book with your work email.
Novasenta Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UPMC | Series A |
| UPMC Enterprises | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 43% to 2,029.
- Feb 5, 2024
$15M round closed.
For institutional investors. Book with your work email.
Novasenta Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Novasenta's valuation, stock price, and market status.
Is Novasenta a public or private company?
Novasenta is a private company.
What is the current stock price of Novasenta?
Novasenta is a private company, so its shares have no public market price. Caplight tracks Novasenta's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Novasenta worth (valuation)?
Novasenta's valuation is estimated at $78.0M based on funding round data.
Can I buy Novasenta stock?
Novasenta shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Novasenta's last funding round?
Novasenta's most recent funding round was Series B on February 5, 2024.
Who are the main investors in Novasenta?
Key investors in Novasenta include UPMC, UPMC Enterprises.
Will Novasenta IPO soon?
No public IPO plans have been announced for Novasenta.
How can I track Novasenta secondary market activity?
Caplight tracks bids, offers, and trades in Novasenta's shares on secondary markets.